复方鳖甲软肝片联合恩替卡韦治疗代偿期乙型肝炎肝硬化的疗效观察

Clinical effect observation of Fufang Biejia Ruangan Tablet combined with entecavir in treating decompensated hepatitis B cirrhosis

目的:探究复方鳖甲软肝片与恩替卡韦联合治疗代偿期乙型肝炎肝硬化临床效果。方法:选取我院2013年3月—2015年2月收治的84例代偿期乙型肝炎肝硬化患者,依据治疗方法分为单一组与联合组,每组42例。单一组予以恩替卡韦治疗,于此基础上,联合组予以复方鳖甲软肝片治疗。观察统计两组患者临床效果。结果:两组总有效率对比,联合组88.10%明显高于单一组69.05%,差异有统计学意义(P<0.05)。结论:对代偿期乙型肝炎肝硬化患者予以复方鳖甲软肝片与恩替卡韦联合治疗疗效显著。

Objective：To explore the clinical effect of Fufang Biejia Ruangan Tablet combined with entecavir in treating decompensated hepatitis B cirrhosis. Methods： 84 cases of patients with decompensated chronic hepatitis B cirrhosis treated in our hospital from March 2013 to February 2015 were selected divided into the single treatment group and the combination group according to different treatment methods, with 42 cases in each group. The single treatment group received entecavir treatment and the combination group received Fufang Biejia Ruangan Tablet combined with entecavir. The clinical effect of two groups of patients was observed and statistically analyzed. Results：The total effective rate of the combination group was 88.i0%, which was significantly higher than that of the single treatment group, 69.05%, the difference was statistically significant （P 〈 0.05）. Conclusion： Fufang Biejia Ruangan Tablet combined with entecavir had significant curative effect in treating patients with decompensated hepatitis B cirrhosis.